Show simple item record

dc.contributor.authorMuñoz‐San Martín, Cristina
dc.contributor.authorPérez‐Ginés, Víctor
dc.contributor.authorTorrente‐Rodríguez, Rebeca M.
dc.contributor.authorGamella, Maria
dc.contributor.authorSolis-Fernandez, Guillermo 
dc.contributor.authorMontero-Calle, Ana Maria 
dc.contributor.authorPedrero, María
dc.contributor.authorSerafín, Verónica
dc.contributor.authorMartínez‐Bosch, Neus
dc.contributor.authorNavarro, Pilar
dc.contributor.authorGarcía de Frutos, Pablo
dc.contributor.authorBatlle, Montserrat
dc.contributor.authorBarderas Manchado, Rodrigo 
dc.contributor.authorPingarrón, José M.
dc.contributor.authorCampuzano, Susana
dc.date.accessioned2022-07-19T07:42:40Z
dc.date.available2022-07-19T07:42:40Z
dc.date.issued2021
dc.identifier.citationElectrochem. Sci. Adv.2021;e2100096.es_ES
dc.identifier.issn2698-5977es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14726
dc.description.abstractGrowth arrest-specific 6 (GAS6) protein plays a key role in processes related toproliferation,inflammation,angiogenesis,andatheroscleroticplaqueformation.In addition, it has been reported that plasma levels of GAS6 are related to cancerprognosis and other relevant pathologies, such as heart failure or sepsis. Wereport here the first electrochemical immunoplatform for the determination ofGAS6, which has demonstrated to be competitive with other available method-ologies in terms of cost, simplicity, and decentralized application. The developedimmunoplatform involves a sandwich immunoassay using magnetic microparti-cles (MBs) and uses amperometric detection at disposable screen-printed carbonelectrodes (SPCEs). The MBs were modified with an antibody specific to GAS6for its selective capture, which is further recognized by a biotinylated secondaryantibody subsequently labeled with a streptavidin-horseradish peroxidase(Strep-HRP) conjugate. The electrochemical detection was carried out using thehydroquinone (HQ)/H2O2system. The developed bioplatform exhibits a greatselectivity and low limit of detection (27 pg/mL) that allowed the determinationof the GAS6 circulating level in plasma samples from patients suffering heartfailure (HF) and diagnosed with pancreatic ductal adenocarcinoma (PDAC),as well as the determination of the target protein in raw secretomes of humancolorectal cancer cell lines.es_ES
dc.description.sponsorshipThis work is part of the POSITION-II project funded by the ECSEL Joint Undertaking under grant number Ecsel-783132-Position-II-2017-IA; www.position-2.eu, and PCI2018-093067 (Spanish Ministerio de Ciencia e Innovación) to M.P. The financial support of PID2019-103899RB-I00 (Spanish Ministerio de Ciencia e Innovación) Research Project to S.C., PI17CIII/00045 and PI20CIII/00019 grants from the AES-ISCIII program to R.B. and the TRANSNANOAVANSENS-CM Program from the Comunidad de Madrid (Grant S2018/NMT-4349) to S.C., RTI2018-095672-B-I00 (Spanish Ministerio de Ciencia e Innovación) to P.G.F.; Fundació la Marató de TV3 project 081010 to M.B.; research project PI20/00625, from the AES-ISCIII/FEDER program, to P.N, are gratefully acknowledged. A. Montero-Calle acknowledges the support of the FPU predoctoral contracts by the Spanish Ministerio de Educación, Cultura y Deporte. G.S-F. is recipient of a predoctoral contract (grant number 1193818N) supported by The Flanders Research Foundation (FWO). C. Muñoz-San Martín acknowledges a predoctoral contract from Complutense University of Madrid. R.M. Torrente-Rodríguez acknowledges a Talento-Contract from Comunidad de Madrid (2019-T2/IND-15965).es_ES
dc.language.isoenges_ES
dc.publisherWiley es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAmperometrices_ES
dc.subjectGAS6es_ES
dc.subjectIimmunosensores_ES
dc.subjectPlasmaes_ES
dc.subjectSecretomees_ES
dc.titleElectrochemical immunosensing of Growth arrest‐specific 6 in human plasma and tumor cell secretomeses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.format.volume2021es_ES
dc.format.pagee2100096.es_ES
dc.identifier.doi10.1002/elsa.202100096es_ES
dc.contributor.funderECSEL Joint Undertakinges_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderComunidad de Madrid (España) es_ES
dc.contributor.funderFundación La Marató TV3 es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderResearch Foundation - Flanders es_ES
dc.contributor.funderComplutense University of Madrid (España) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2698-5977es_ES
dc.relation.publisherversionhttps://doi.org/10.1002/elsa.202100096es_ES
dc.identifier.journalElectrochemical Science Advanceses_ES
dc.repisalud.centroISCIII::Unidad Funcional de Investigación de Enfermedades Crónicas (UFIEC)es_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTAEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2019-103899RB-I00, AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-095672-B-I00es_ES
dc.relation.projectFECYTAEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-095572-B-I00, AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-095672-B-I00, AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2017-89791-Res_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PCI2018-093067es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI17CIII/00045es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI20CIII/00019es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI20/00625es_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional